Meet the Team
Celling Biosciences is a collaboration between physicians, scientists and engineers. This collaboration provides the opportunity for scientific theory to drive biotechnology advancement for optimal clinical outcomes. The team at Celling Biosciences is pioneering autologous cell therapy at the scientific level by optimizing the collection, processing and delivery of cells through sophisticated bio-engineered systems.
Executive Leadership
Kevin Dunworth
CEO
Kevin Dunworth, Founder of Celling Biosciences, has spent more than 26 years in the orthopedic industry and brings a wealth of expertise in all aspects of the business. Dunworth has run medical companies in the Middle East, Eastern and Western Europe, and the United States. He excelled in various executive positions before founding VCD Medical, in Austin, Texas. For the past eight years, Dunworth has successfully built a world-class distribution business, which provides a variety of orthopedic and biologic products. Dunworth’s leadership roles within the orthopedic industry have included, Director of Emerging Markets and Director of European Sales for Smith & Nephew; Director of International Sales, Vice President of Worldwide Sales and Vice President for FlouroScan International and Vice President of Sales for TransLeasing and Vice President for TransLeasing GE.
Steve Melchiode
President
Steve Melchiode is an experienced entrepreneur and business development professional with a focus on startup companies in the technology and healthcare sectors. Currently, Steve is the President at Celling Biosciences, a regenerative medicine and cell therapy R&D company, where he oversees a team of 75 in all operations, fundraising, sales, international development, legal and regulatory compliance activities. Steve has been with Celling Biosciences since its inception in 2006 as a medical device company and has been leading the company’s strategic development for more than a decade. Additionally, Steve has been a driving force behind the company’s evolution toward specialization in the regenerative medicine and cell therapy space. In addition to securing over $10 million in financing, Steve has been a driving force to revenue growth, moving annual revenue to over $20 million and recently leading international development efforts by opening the company’s first overseas office in Brazil, with plans to expand into Europe later this year.
Social Links